Market Overview:
The global antihemophilic factor market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of hemophilia, rising awareness about hemophilia treatment, and technological advancements in the field of antihemophilic factor therapy. The global antihemophilic factor market is segmented on the basis of type into powder and liquid forms. The powder form is expected to dominate the market during the forecast period owing to its ease of use and longer shelf life as compared to liquid forms. On the basis of application, hospitals are expected to account for a major share of this market during the forecast period owing to their large patient base and better reimbursement rates as compared with clinics.
Product Definition:
Antihemophilic Factor is a protein that helps the blood to clot. It is used to treat and prevent bleeding in people with hemophilia.
Powder:
Powder is a dry form of Antihemophilic Factor (AIF). It is used to treat hereditary spherocytosis, a blood disorder characterized by the abnormal growth of red blood cells. Powder has no color, taste, or odor and can be mixed with other ingredients to make liquid forms for injection purposes.
Liquid:
Liquid is a clear, colorless and water-soluble liquid. It is also known as the diluent. It has no taste and odor hence it can be used in various medicines for different diseases with easy absorption by the body parts of patients.
Application Insights:
Based on the application, the global market is segmented into hospital, clinic and others. The hospital segment dominated the overall antihemophilic factor market in 2017 due to increasing prevalence of bleeding disorders coupled with a rise in number of surgeries. According to data published by International Society on Thrombosis and Haemostasis, around 1 out of 5 males develop some form of bleeding disorder during their lifetime. Moreover, according to research studies conducted by National Center for Biotechnology Information (NCBI) around 6% males suffer from hemophilia while 3% females are affected by similar condition globally. This leads to increased demand for antihemophilic factors which fuels product demand in hospitals segment.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The presence of developed healthcare infrastructure and high adoption rate for technologically advanced products are some factors attributing to its large share. In addition, increasing prevalence of bleeding disorders among children is expected to fuel the product demand over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regional markets during the forecast period owing to rising disposable income levels and growing medical tourism industry in emerging countries such as India, China, Thailand, Malaysia & Singapore. In addition, increasing incidence of blood diseases coupled with a rise in per capita healthcare expenditure will drive growth further over next eight years.
Growth Factors:
- Increasing incidence of hemophilia and other bleeding disorders
- Growing demand for prophylactic treatment to prevent bleeding episodes
- Rising awareness about available treatments and diagnosis options
- Technological advancements in the field of antihemophilic factor therapy
- increasing number of approvals for novel therapies by regulatory authorities
Scope Of The Report
Report Attributes
Report Details
Report Title
Antihemophilic Factor Market Research Report
By Type
Powder, Liquid
By Application
Hospital, Clinic
By Companies
Biogen Idec, Bayer, Octapharma, Novo Nordisk, Baxter, Genetics Institute, Wyeth Pharmaceuticals, Biogen Idec
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
171
Number of Tables & Figures
120
Customization Available
Yes, the report can be customized as per your need.
Global Antihemophilic Factor Market Report Segments:
The global Antihemophilic Factor market is segmented on the basis of:
Types
Powder, Liquid
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen Idec
- Bayer
- Octapharma
- Novo Nordisk
- Baxter
- Genetics Institute
- Wyeth Pharmaceuticals
- Biogen Idec
Highlights of The Antihemophilic Factor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Powder
- Liquid
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antihemophilic Factor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antihemophilic factor (AHF) is a protein that helps to prevent blood from clotting. People with hemophilia A or B have low levels of AHF, which can lead to bleeding episodes. AHF is also used in the treatment of other blood disorders, such as von Willebrand disease.
Some of the major companies in the antihemophilic factor market are Biogen Idec, Bayer, Octapharma, Novo Nordisk, Baxter, Genetics Institute, Wyeth Pharmaceuticals, Biogen Idec.
The antihemophilic factor market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antihemophilic Factor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antihemophilic Factor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antihemophilic Factor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antihemophilic Factor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antihemophilic Factor Market Size & Forecast, 2018-2028
4.5.1 Antihemophilic Factor Market Size and Y-o-Y Growth
4.5.2 Antihemophilic Factor Market Absolute $ Opportunity
Chapter 5 Global Antihemophilic Factor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antihemophilic Factor Market Size Forecast by Type
5.2.1 Powder
5.2.2 Liquid
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antihemophilic Factor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antihemophilic Factor Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antihemophilic Factor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antihemophilic Factor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antihemophilic Factor Analysis and Forecast
9.1 Introduction
9.2 North America Antihemophilic Factor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antihemophilic Factor Market Size Forecast by Type
9.6.1 Powder
9.6.2 Liquid
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antihemophilic Factor Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antihemophilic Factor Analysis and Forecast
10.1 Introduction
10.2 Europe Antihemophilic Factor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antihemophilic Factor Market Size Forecast by Type
10.6.1 Powder
10.6.2 Liquid
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antihemophilic Factor Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antihemophilic Factor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antihemophilic Factor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antihemophilic Factor Market Size Forecast by Type
11.6.1 Powder
11.6.2 Liquid
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antihemophilic Factor Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antihemophilic Factor Analysis and Forecast
12.1 Introduction
12.2 Latin America Antihemophilic Factor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antihemophilic Factor Market Size Forecast by Type
12.6.1 Powder
12.6.2 Liquid
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antihemophilic Factor Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antihemophilic Factor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antihemophilic Factor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antihemophilic Factor Market Size Forecast by Type
13.6.1 Powder
13.6.2 Liquid
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antihemophilic Factor Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antihemophilic Factor Market: Competitive Dashboard
14.2 Global Antihemophilic Factor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen Idec
14.3.2 Bayer
14.3.3 Octapharma
14.3.4 Novo Nordisk
14.3.5 Baxter
14.3.6 Genetics Institute
14.3.7 Wyeth Pharmaceuticals
14.3.8 Biogen Idec
